Ms. Megan McCrae reports

ORGANIGRAM FURTHER EXPANDS GLOBAL PORTFOLIO WITH LAUNCH OF EDISON AND BOXHOT MEDICAL VAPES AND PASTILLES IN AUSTRALIA

Organigram Global Inc. has expanded its international product portfolio with the launch of Edison and Boxhot medical cannabis vape and pastille products in Australia.

Australia has become one of the world's most dynamic medical cannabis markets, with increasing approvals for access and prescribers utilizing a broader range of dosage forms1. While flower remains a core category, alternatives such as vapes and pastilles are gaining importance, driven by demand for consistent dosing, ease of administration and discreet, ready-to-use formats. These trends position Organigram, recognized for its expertise in developing high-quality, non-flower cannabis product formats anchored in need-state specific formulations, to have a central role as the market evolves.

"Australia represents an exciting international opportunity in medical cannabis, and we are entering the market at a pivotal moment with an informed strategy. The launch of Organigram brands in Australia coincides with our proposed acquisition of Sanity Group, one of Germany's leading cannabis companies, marking a significant step in our international expansion," said Megan McCrae, senior vice president, corporate strategy and international growth, at Organigram. "Together, these strategic moves underscore Organigram's commitment to broadening its global reach and reinforcing our reputation as a trusted supplier of medical cannabis. By integrating established brands from the Canadian market, with a diverse range of science-led innovative product formats, we are positioning Organigram to serve leading regulated medical cannabis markets globally, delivering consistent quality and reliability to patients across Australia and beyond."

Organigram already supplies indoor-grown flower to the Australian market through existing B2B (business-to-business) supply relationships. With this expansion, the company is introducing 10 product SKUs (stock-keeping units) in Australia across its Edison and Boxhot brands. Edison vapes will feature single-strain live terpenes extracted from Canada's top-selling cultivars, with the terpenes shipped to Australia. The pastilles range will feature an array of established formulations developed with specific patient experiences in mind. Boxhot on the other hand will feature three of the top-selling botanical blends in Canada in the company's proprietary wide-bodied 1.2-gram cartridges, offering patients more volume per product. These formats reflect the company's belief that future global growth in medical cannabis will be driven by ready-to-consume products and anchored in science and standards, where Organigram has built a competitive advantage through years of science-led innovation and product development.

"Australia is a rapidly evolving medical market where we see momentum in ready-to-consume formats beyond traditional flower. As patient and clinician preferences continue to move toward reliable, convenient, non-flower options that are grounded in science, data and rigorous quality standards, Organigram is well positioned to participate in this next phase of growth," said Borna Zlamalik, senior vice-president, innovation and international research and development. "Our industry-leading focus on science and clinical validation -- combined with our experience developing high-quality, non-flower products in Canada -- give us a unique advantage as we introduce our established Canadian brands and product offerings to the Australian market."

Organigram's products will be available through its distribution partnership with Leafio, the wholesale distribution arm of Montu Australia, one of Australia's leading medical cannabis distributors. Through this arrangement, Organigram's medical cannabis products are expected to be available to more than 4,000 pharmacies via Leafio's nationwide supply chain.

Organigram will debut its new product lineup as a sponsor at the United in Compassion (UIC) Medical Cannabis Symposium, taking place Feb. 26 to Feb. 28 in Brisbane, where Mr. Zlamalik will be a featured speaker at the event's Scientific Program, delivering an address titled "From Potency to Predictability: Engineering Confidence in Medical Cannabis." The conference provides a platform to introduce Organigram's medical cannabis product portfolio to clinicians, researchers and industry participants across Australia.

About Organigram Global Inc.

Organigram Global is a Nasdaq Global Select Market- and Toronto Stock Exchange-listed company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project, Organigram Global participates in the United States and Canadian cannabinoid beverage markets. Organigram is focused on producing high-quality cannabis for adult consumers, as well as developing international business relationships to extend the company's global footprint. Organigram has developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, Shred, Shred'ems, Monjour, Tremblant Cannabis, Collective Project, Trailblazer, Boxhot and Debunk. Organigram operates facilities in Moncton, N.B., and Lac Superieur, Que., with a dedicated edibles manufacturing facility in Winnipeg, Man. The company also operates two additional cannabis processing facilities in Southwestern Ontario, one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 (carbon dioxide) and hydrocarbon extraction capabilities, and is optimized for formulation refinement, postprocessing of minor cannabinoids and preroll production. The facility in London is optimized for labelling, packaging and national fulfilment. The company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations (Canada).

We seek Safe Harbor.